title: The current state of hormonal therapy for prostate cancer.
abstract: Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics.
authors.affiliation: Division of Hematology and Oncology, University of Michigan Medical Center, Ann Arbor, USA.
authors.forename: Beth A
authors.initials: BA
authors.lastname: Hellerstedt
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Pienta
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003534:Cyproterone / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
chemical_list: D000726:Androgen Antagonists; D004365:Drugs, Chinese Herbal; D006728:Hormones; D010936:Plant Extracts; C114209:herbal preparation PC-SPES; D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D003534:Cyproterone